SCHEMBL7008253

SCHEMBL7008253

OCCCCCCCCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.65
ALOX15 P16050 2/20 0.65
PNMT P11086 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
PYGL P06737 1/20 0.50
SIGMAR1 Q99720 10/20 0.49
IDO1 P14902 1/20 0.47
HDAC6 Q9UBN7 1/20 0.46
CA2 P00918 1/20 0.44
BCHE P06276 2/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10609252 1.00 IGF1R (0.65) IGF1RALOX15PNMTTAAR1PYGL
SCHEMBL8905783 1.00 IGF1R (0.65) IGF1RALOX15PNMTTAAR1PYGL
SCHEMBL9026682 0.98 IGF1R (0.67) IGF1RALOX15PNMTTAAR1PYGL
SCHEMBL81497 0.92 IGF1R (0.63) IGF1RALOX15PNMTTAAR1PYGL
SCHEMBL9241133 0.83 AHR (0.50) IGF1RALOX15PNMTTAAR1SIGMAR1
SCHEMBL908524 0.83 PNMT (0.61) IGF1RALOX15PNMTTAAR1PYGL
SCHEMBL15689781 0.81 IGF1R (0.47) IGF1RALOX15PNMTTAAR1SIGMAR1
SCHEMBL11332028 0.80 PNMT (0.70) IGF1RALOX15PNMTTAAR1PYGL
SCHEMBL22333700 0.80 SIGMAR1 (0.61) IGF1RALOX15PNMTTAAR1SIGMAR1
SCHEMBL11332990 0.80 PNMT (0.70) IGF1RALOX15PNMTTAAR1PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028955-B1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 2003-07-16 EP disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 US disclosed
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C IGF1R 3836/4885ALOX15 66/4885PNMT 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.